AstraZeneca plc (ADR) (AZN) Releases Earnings Results, Misses Expectations By $-0.01 EPS

AstraZeneca plc (ADR) (AZN) reported quarterly earnings results on Friday, Apr-29-2016. The company reported $0.95 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $0.96. The company posted revenue of $6115.00 million in the period, compared to analysts expectations of $5977.19 million. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Downgraded by Goldman to ” Sell” on Apr 12, 2016. AstraZeneca plc (ADR) was Downgraded by Jefferies to ” Hold” on Mar 15, 2016. AstraZeneca plc (ADR) was Initiated by Cantor Fitzgerald to “Buy” on Feb 26, 2016.

AstraZeneca plc (ADR) closed down -0.18 points or -0.61% at $29.42 with 48,06,900 shares getting traded on Wednesday. Post opening the session at $29.37, the shares hit an intraday low of $29.31 and an intraday high of $29.58 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).

AstraZeneca plc (ADR)

Leave a Reply

AstraZeneca plc (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on AstraZeneca plc (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.